Podcasts about cardiometabolic diseases

Regular exercise is one of the most effective methods to keep the heart healthy and efficient. In rare cases, however, there are reports of athletes collapsing mid-game due to cardiac arrest. And while exercise is generally also a key part of the rehabilitation process for those who've experienced cardiac events, caution should still be taken. This is where physician input is important, and where testing and regular monitoring can be implemented to reduce the risk of further events. Today, we're joined by experts in the fields of sports cardiology and exercise physiology, as well as an athlete with firsthand experience in the matter, to draw attention to the topic of cardiac health and how it pertains to sports medicine. In this episode, host Myra Cocker, Assistant Professor of Cardiology at Houston Methodist Hospital and Global Director of Clinical Science for Cardiovascular Ultrasound at Siemens Healthineers, welcomes Dr. Jonathan Kim, Associate Professor and Founding Director at Emory University Sports Cardiology and Team Cardiologist for Georgia Tech, the Atlanta Falcons, Hawks, and Braves; as well as Dr. Dominique Hansen, Professor of Rehabilitation and Exercise Physiology in Cardiometabolic Diseases at Universiteit Hasselt in Belgium and Secretary of the European Association of Preventive Cardiology; and retired professional soccer player and cardiology patient Daniel Engelbrecht. What you'll learn in this episode:How cardiac risk can affect older and younger elite athletes differentlyCardiac events can stem from myocarditis, caused by an infectious disease.Red flag symptoms when it comes to cardiac events while exercising, including intense chest pressure or loss of consciousnessThe use of Automated External Defibrillators is a critical first response strategy in the event of cardiac arrest.Implementation of an exercise program can be essential when treating a patient who has experienced, or is at risk for, cardiovascular disease.For patients who have suffered from major cardiac events, their timeline for return to sports or intense physical activity is heavily dependent on a number of individual factors.Connect with Myra CockerLinkedInConnect with Jonathan KimLinkedInConnect with Dominique HansenLinkedInConnect with Daniel EngelbrechtLinkedIn Hosted on Acast. See acast.com/privacy for more information.

In this episode of Functional Medicine Foundations, Dr. Mark Holthouse takes us on a journey to optimal health, focusing on Metabolic Weight Loss, GLP1 Agonists, and Cardiometabolic Risk Factors. Uncover the secrets of metabolic mastery, explore the transformative power of GLP1 Agonists, and gain insights beyond conventional weight loss approaches. Dr. Holthouse, a leading figure in Functional Medicine, empowers listeners with practical strategies to take charge of their metabolism and understand critical factors influencing cardiometabolic health. Join us for an illuminating discussion that bridges the gap between science and holistic wellness. It's time to embark on the road to inside-out wellness!

Today, we examine the impact of ultra-processed foods on liver health. This shift in our diet has had an impact on our liver health, resulting in the important organ not functioning properly, for us and our kids. Dr. Elizabeth Boham presents a case-study of a patient she had who had developed non-alcoholic fatty liver disease and what she did to help him. Many of us turn to cleanses to detox our livers, but what if we instead reduced our reliance on ultra-processed foods instead?   LET'S TALK THE WALK! ***NEW*** Facebook Group for Our Community! Join here for support, motivation and fun! Wellness While Walking Facebook page Wellness While Walking on Instagram Wellness While Walking on Twitter Wellness While Walking website for show notes and other information wellnesswhilewalking@gmail.com Wellness While Walking on Threads     RESOURCES AND SOURCES (some links may be affiliate links) FATTY LIVER DISEASE (NAFLD/MDASLD) AND ULTRA-PROCESSED FOODS Fatty Liver Was a Disease of the Old. Then Kids Started Getting Sick, washingtonpost.com Metabolic Dysfunction-Associated Steatotic Liver Disease, my.clevelandclinic.org Ultra-Processed Food Intake is Associated with Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review and Meta-Analysis, ncbi.nlm.nih.gov Non-Alcoholic Fatty Liver Disease, my.clevelandclinic.org The Nova Food Classification System, ecuphysicians.ecu.edu Consumption of Ultraprocessed Foods and Risk of Multimorbility of Cancer and Cardiometabolic Diseases, thelancet.com Some Ultra-Processded Foods Are Good for Your Health, WHO-Backed Study Finds, theguardian.com Eating Ultra-Processed Foods Puts Your Liver At Risk, New Study Warns, news-medical.net Avoid This Diet to Prevent FATTY LIVER DISEASE - Mark Hyman, MD, youtube.com   HOW TO SHARE WELLNESS WHILE WALKING Tell a friend or family member about Wellness While Walking, maybe while you're walking together or lamenting not feeling 100% Follow up with a quick text with more info, as noted below! (My favorite is pod.link/walking because it works with all the apps!) Screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Wellness While Walking on Apple – click the up arrow to share with a friend via text or email, or share to social media Wellness While Walking on Spotify -- click the up arrow to share with a friend via text or email, or share to social media Use this universal link for any podcast app: pod.link/walking – give it to friends or share on social media Tell your pal about the Wellness While Walking website Thanks for listening and now for sharing! : )       DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking.     Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!

Hear cardiologist Dr. Nehal Mehta, Chief, Section of Inflammation and Cardiometabolic Diseases at the NIH in Bethesda, MD provide an update on the role "adipokines" play in the development of inflammatory diseases such as psoriasis, along with tips on reducing your inflammatory risk. This Psound Bytes episode is provided with support from AbbVie, Amgen, CeraVe, Bristol Myers Squibb, Janssen and Lilly.

Tune in to listen to Joe E. Pizzorno, ND, one of the world's leading experts on science-based natural and integrative medicine, talk about the impact of environmental toxins in the development and exacerbation of cardiometabolic diseases, as well as what clinicians and patients can do to lower their burden on health and outcomes. Also, please don't forget to rate, subscribe/follow, and leave us a 5-star review!

Herbs and spices are recommended to increase flavor and displace salt in the diet. Accumulating evidence suggests herbs and spices may improve risk factors for cardiometabolic diseases. In this episode we speak with Kristina Petersen, who co-authored this paper on a review of human clinical trials and studies on the effect of herbs and spices on risk factors for cardiometabolic diseases.

PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist

This week, Dr Ferghal and Dr Saveena discuss the benefits of exercise both in primary and secondary prevention of cardiometabolic diseases, heart disease and maintaining a robust immune system. Support the show (https://www.patreon.com/medheads)

Hear dermatologist Dr. Mark Lebwohl, Mt. Sinai Health System, cardiologist Dr. Nehal Mehta and Dr. Heather Teague from the NIH Section of Inflammation and Cardiometabolic Diseases discuss the effect of systemic psoriasis treatments on CVD, diabetes and psoriatic arthritis. For disclosures/credits: https://www.eeds.com/em/2172. This program is supported by educational grants from AbbVie, Amgen, Janssen and UCB. To access articles mentioned https://bit.ly/2MKjlrB .

Hear dermatologist Dr. Mark Lebwohl, Mt. Sinai Health System, cardiologist Dr. Nehal Mehta and Dr. Heather Teague from the NIH Section of Inflammation and Cardiometabolic Diseases discuss the effect of systemic psoriasis treatments on CVD, diabetes and psoriatic arthritis. For disclosures/credits: https://www.eeds.com/em/2172. This program is supported by educational grants from AbbVie, Amgen, Janssen and UCB. To access articles mentioned https://bit.ly/2MKjlrB .

An estimated 47 million Americans are living with cardiometabolic diseases, according to the American College of Cardiology. Cardiometabolic diseases are interrelated conditions that include cardiovascular diseases, such as heart disease, stroke, and hypertension, as well as metabolic diseases, such as Type 2 diabetes, obesity and nonalcoholic fatty liver disease. Patients with cardiometabolic diseases have a higher risk of not only developing COVID-19, but also developing complications related to COVID-19. On the Mayo Clinic Q&A podcast, Dr. Stephen Kopecky, a Mayo Clinic cardiologist, discusses lifestyle factors that affect cardiometabolic diseases and how COVID-19 can damage the heart.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

From Smog hanging over cities, to smoke inside the home, air pollution poses a major threat to health and climate. This episode discusses the types, causes, health and effects of Air Pollution, as well as it preventive measures. Tijani Olawale Abogunloko, MD, MSc. Is a medical doctor with a medical degree from the Dalian Medical University, China, and a double master's degree in Biomedical Sciences from the University of Freiburg, Germany, and the University of Buenos Aires, Argentina, respectively. Currently a research assistant with the Vascular Immunology Lab, University Heart Center, Freiburg, Germany. His research interests focises on Air Pollution and Cardiometabolic Diseases. Connect with him via IG: @Olawale-Tj, Facebook : Tijani Abogunloko, Email: sheugsd@yahoo.com

Hear the latest news about the association between psoriasis and cardiovascular disease - from lipoproteins and inflammation to the metabolic bin, and how treatments can impact health risks from cardiologist Dr. Nehal Mehta, Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD. To view disclosure information and claim credit, go to https://www.eeds.com/em/1137 .

Hear the latest news about the association between psoriasis and cardiovascular disease - from lipoproteins and inflammation to the metabolic bin, and how treatments can impact health risks from cardiologist Dr. Nehal Mehta, Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD. To view disclosure information and claim credit, go to https://www.eeds.com/em/1137 .

'The risk is real but..." says Dr. Nehal Mehta, cardiologist and Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD. Hear Dr. Mehta discuss risks associated with cardiovascular disease, the metabolic arena, treatments and what can be done to reduce the risk of cardiovascular disease with psoriatic disease. All new information! This guidelines activity is supported by grant funding from Bausch Health Foundation, Celgene and Novartis. 

Learn what drives the heart and psoriatic disease connection and why even one plaque may be too much from Dr. Nehal Mehta, a cardiologist who is Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD. Dr. Mehta provides an update on his research around the impact of systemic inflammation using PET imaging. 

Dr. Nehal Mehta, a nuclear cardiologist who is Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD, talks about his research in understanding the role of innate immunity and inflammation in psoriatic disease, and how it relates to cardiovascular and metabolic diseases. To view disclosure information and claim credit, go to https://www.eeds.com/em/1113 . This program is supported by unrestricted educational grants from Bristol-Myers Squibb, Lilly and Ortho Dermatologics. To access other CME activities visit https://cme.psoriasis.org . 

Dr. Nehal Mehta, a nuclear cardiologist who is Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD, talks about his research in understanding the role of innate immunity and inflammation in psoriatic disease, and how it relates to cardiovascular and metabolic diseases. To view disclosure information and claim credit, go to https://www.eeds.com/em/1113 . This program is supported by unrestricted educational grants from Bristol-Myers Squibb, Lilly and Ortho Dermatologics. To access other CME activities visit https://cme.psoriasis.org . 

Psoriasis is an inflammatory skin disease associated with increased cardiovascular risk. Dr. Nehal Mehta currently directs the largest ongoing cohort study to date in psoriasis, and his research is showing that local inflammation in different areas of the body such as the teeth, scalp, knees, skin, or gut has systemic consequences, and treating that local inflammation can help heal heart disease. Nehal Mehta, M.D., M.S.C.E., F.A.H.A., is the inaugural NIH Lasker Clinical Research Scholar and a Principal Investigator in the Section of Inflammation and Cardiometabolic Diseases at the NIH's National Heart, Lung, and Blood Institute (NHLBI). Learn more about Dr. Mehta and his research at https://irp.nih.gov/pi/nehal-mehta

Commentary by Dr. Valentin Fuster